Author:
Parikh S.,Murray L.,Kenning L.,Bottomley D.,Din O.,Dixit S.,Ferguson C.,Handforth C.,Joseph L.,Mokhtar D.,White L.,Wright G.,Henry A.M.
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Reference17 articles.
1. EU science hub. European commission's science and knowledge service. Available at: https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe.
2. Ra-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease;Harrison;Cancer Manag Res,2013
3. Alpha emitter Ra-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013
4. National Institute of Health and Care Excellence. Ra-223 dichloride for treating hormone relapsed prostate cancer with bone metastases. Technology Appraisal Guidance [TA412]. Published 28 September 2016. Available at: www.nice.org.uk/guidance/TA412/chapter/1-Recommendations.
5. Yorkshire and Humber NHS clinical senate. Available at: www.yhsenate.nhs.uk.
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献